Technical Analysis for LLY - Eli Lilly and Company

Grade Last Price % Change Price Change
A 246.51 1.20% 2.93
LLY closed up 1.2 percent on Wednesday, July 28, 2021, on 50 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Aug 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical LLY trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Signal Line Cross Bullish 1.20%
Narrow Range Bar Range Contraction 1.20%
NR7 Range Contraction 1.20%
Older End-of-Day Signals for LLY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 14 hours ago
60 Minute Opening Range Breakout about 16 hours ago
Up 1% about 18 hours ago
New 52 Week High about 18 hours ago
Rose Above Previous Day's High about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Eli Lilly and Company Description

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; bipolar depression and treatment-resistant depression; and brain imaging of beta-amyloid plaques. Its endocrinology products treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. The company's oncology products treat malignant pleural mesothelioma; pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as cardiovascular products, which are used treat erectile dysfunction, benign prostatic hyperplasia, high cholesterol, pulmonary arterial hypertension; reduce thrombotic cardiovascular events; and used as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to improve milk productivity in dairy cows; anticoccidial agents; antibiotics to control enteric infections in calves and swine; products to treat canine separation anxiety; products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections; and other pharmaceutical products to treat staphylococcal and bacterial infections. The company distributes its products through independent wholesale distributors; and directly to pharmacies. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Diabetes Pharmaceutical Products Neuroscience Hypertension Alzheimer's Disease Mental Health Health Products Animal Health Antibiotic Dysfunction Wholesale Distributor Schizophrenia Wholesale Distributors Dogs Milk Psychiatric Diagnosis Psychiatry Pulmonary Arterial Hypertension Bacterial Infections Cholesterol Antibiotics Major Depressive Disorder Amyloid Cattle Depression Depressive Disorder Animal Health Products Head And Neck Cancer Attention Deficit Hyperactivity Disorder Endocrinology Helio Osteoporosis Bipolar Disorder Growth Hormone Hyperactivity Disorder Hyperplasia Testosterone Vascular Products Benign Prostatic Hyperplasia Obsessive Compulsive Disorder Percutaneous Cardiovascular Products Mesothelioma Treatment Resistant Depression Growth Hormone Deficiency Head And Neck Cancers Major Depressive Disorders Mood Disorders Oncology Products Psychology Bipolar Depression Bulimia Nervosa Erectile Dysfunction Panic Disorder Percutaneous Coronary Intervention Respiratory And Other Diseases Testosterone Deficiency

Is LLY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 248.4
52 Week Low 129.21
Average Volume 3,300,006
200-Day Moving Average 188.03
50-Day Moving Average 222.90
20-Day Moving Average 236.60
10-Day Moving Average 238.63
Average True Range 4.18
ADX 44.29
+DI 40.68
-DI 10.41
Chandelier Exit (Long, 3 ATRs) 235.85
Chandelier Exit (Short, 3 ATRs) 239.43
Upper Bollinger Bands 245.52
Lower Bollinger Band 227.68
Percent B (%b) 1.06
BandWidth 7.54
MACD Line 5.73
MACD Signal Line 5.47
MACD Histogram 0.2583
Fundamentals Value
Market Cap 235.81 Billion
Num Shares 957 Million
EPS 6.11
Price-to-Earnings (P/E) Ratio 40.33
Price-to-Sales 5.72
Price-to-Book 28.85
PEG Ratio 1.14
Dividend 2.96
Dividend Yield 1.20%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 255.15
Resistance 3 (R3) 254.82 251.61 253.71
Resistance 2 (R2) 251.61 249.41 251.78 253.23
Resistance 1 (R1) 249.06 248.05 250.34 249.39 252.75
Pivot Point 245.85 245.85 246.49 246.02 245.85
Support 1 (S1) 243.30 243.65 244.58 243.63 240.27
Support 2 (S2) 240.09 242.29 240.26 239.79
Support 3 (S3) 237.54 240.09 239.31
Support 4 (S4) 237.87